EA202190759A1 - Индазолкарбоксамиды в качестве ингибиторов киназ - Google Patents
Индазолкарбоксамиды в качестве ингибиторов киназInfo
- Publication number
- EA202190759A1 EA202190759A1 EA202190759A EA202190759A EA202190759A1 EA 202190759 A1 EA202190759 A1 EA 202190759A1 EA 202190759 A EA202190759 A EA 202190759A EA 202190759 A EA202190759 A EA 202190759A EA 202190759 A1 EA202190759 A1 EA 202190759A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- indazol
- carboxamides
- kinase inhibitors
- ripk1
- soli
- Prior art date
Links
- -1 INDAZOL CARBOXAMIDES Chemical class 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862730611P | 2018-09-13 | 2018-09-13 | |
| PCT/US2019/050721 WO2020056074A1 (en) | 2018-09-13 | 2019-09-12 | Indazole carboxamides as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202190759A1 true EA202190759A1 (ru) | 2021-06-17 |
Family
ID=68073172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202190759A EA202190759A1 (ru) | 2018-09-13 | 2019-09-12 | Индазолкарбоксамиды в качестве ингибиторов киназ |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12084426B2 (enExample) |
| EP (1) | EP3849969B1 (enExample) |
| JP (1) | JP7434294B2 (enExample) |
| KR (1) | KR102793119B1 (enExample) |
| CN (1) | CN112673001B (enExample) |
| AU (1) | AU2019339355A1 (enExample) |
| BR (1) | BR112021004310A2 (enExample) |
| CA (1) | CA3112519A1 (enExample) |
| EA (1) | EA202190759A1 (enExample) |
| ES (1) | ES2945220T3 (enExample) |
| IL (1) | IL281371A (enExample) |
| MX (1) | MX2021002617A (enExample) |
| SG (1) | SG11202102406XA (enExample) |
| WO (1) | WO2020056074A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019089442A1 (en) | 2017-10-30 | 2019-05-09 | Bristol-Myers Squibb Company | Aminoimidazopyridines as kinase inhibitors |
| MX2020007531A (es) | 2018-01-26 | 2020-09-09 | Bristol Myers Squibb Co | Aminopirrolotriazinas como inhibidores de cinasa. |
| US12084426B2 (en) | 2018-09-13 | 2024-09-10 | Bristol-Myers Squibb Company | Indazole carboxamides as kinase inhibitors |
| WO2020056072A1 (en) | 2018-09-13 | 2020-03-19 | Bristol-Myers Squibb Company | 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1) |
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| MX2022003769A (es) * | 2019-10-03 | 2022-04-20 | Bristol Myers Squibb Co | Indazol carboxamidas como inhibidores de cinasas. |
| AR123793A1 (es) | 2020-10-19 | 2023-01-11 | Bristol Myers Squibb Co | Compuestos de triazolopiridinilo como inhibidores de quinasas |
| WO2023119210A1 (ko) | 2021-12-24 | 2023-06-29 | 제일약품주식회사 | Ripk1 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004259012C1 (en) | 2003-07-23 | 2012-08-02 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| RU2418797C2 (ru) | 2004-12-22 | 2011-05-20 | Мемори Фармасьютиклз Корпорейшн | Лиганды никотинового рецептора альфа-7, их получение и применение |
| NZ573735A (en) | 2006-05-19 | 2011-10-28 | Abbott Lab | Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives |
| US8648069B2 (en) * | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
| KR101061599B1 (ko) | 2008-12-05 | 2011-09-02 | 한국과학기술연구원 | 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물 |
| US20110237633A1 (en) | 2008-12-11 | 2011-09-29 | Bijoy Panicker | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| US8455516B2 (en) | 2010-01-15 | 2013-06-04 | Touro University | HIV-1 fusion inhibitors and methods |
| KR20130077390A (ko) | 2011-12-29 | 2013-07-09 | 제이더블유중외제약 주식회사 | 단백질 키나아제 저해활성을 가지는 6-아미노-3-카복스아미도인다졸 유도체 |
| SG10201701649YA (en) | 2012-02-21 | 2017-04-27 | Acraf | 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
| AU2013224313B2 (en) | 2012-02-21 | 2017-03-30 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Use of 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors |
| EP2897949B1 (en) | 2012-09-18 | 2018-01-10 | Bristol-Myers Squibb Company | Iap antagonists |
| EP3463355B1 (en) | 2016-05-26 | 2024-08-28 | Sonic Master Limited | Modulators of dux4 for regulation of muscle function |
| MA46453A (fr) | 2016-10-07 | 2019-08-14 | Bristol Myers Squibb Co | Composés imidazopyridazine utiles en tant que modulateurs de réponses il-12, il-23 et/ou ifn alpha |
| EP3580220B1 (en) | 2017-02-13 | 2021-11-17 | Bristol-Myers Squibb Company | Aminotriazolopyridines as kinase inhibitors |
| WO2019089442A1 (en) | 2017-10-30 | 2019-05-09 | Bristol-Myers Squibb Company | Aminoimidazopyridines as kinase inhibitors |
| MX2020007531A (es) | 2018-01-26 | 2020-09-09 | Bristol Myers Squibb Co | Aminopirrolotriazinas como inhibidores de cinasa. |
| US12084426B2 (en) | 2018-09-13 | 2024-09-10 | Bristol-Myers Squibb Company | Indazole carboxamides as kinase inhibitors |
| WO2020056072A1 (en) | 2018-09-13 | 2020-03-19 | Bristol-Myers Squibb Company | 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1) |
| MX2022003769A (es) | 2019-10-03 | 2022-04-20 | Bristol Myers Squibb Co | Indazol carboxamidas como inhibidores de cinasas. |
-
2019
- 2019-09-12 US US17/274,227 patent/US12084426B2/en active Active
- 2019-09-12 WO PCT/US2019/050721 patent/WO2020056074A1/en not_active Ceased
- 2019-09-12 CN CN201980059544.6A patent/CN112673001B/zh active Active
- 2019-09-12 AU AU2019339355A patent/AU2019339355A1/en not_active Abandoned
- 2019-09-12 JP JP2021513960A patent/JP7434294B2/ja active Active
- 2019-09-12 EA EA202190759A patent/EA202190759A1/ru unknown
- 2019-09-12 BR BR112021004310-1A patent/BR112021004310A2/pt not_active Application Discontinuation
- 2019-09-12 ES ES19779242T patent/ES2945220T3/es active Active
- 2019-09-12 EP EP19779242.7A patent/EP3849969B1/en active Active
- 2019-09-12 KR KR1020217010495A patent/KR102793119B1/ko active Active
- 2019-09-12 CA CA3112519A patent/CA3112519A1/en active Pending
- 2019-09-12 SG SG11202102406XA patent/SG11202102406XA/en unknown
- 2019-09-12 MX MX2021002617A patent/MX2021002617A/es unknown
-
2021
- 2021-03-09 IL IL281371A patent/IL281371A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021002617A (es) | 2021-05-12 |
| CA3112519A1 (en) | 2020-03-19 |
| AU2019339355A1 (en) | 2021-05-13 |
| WO2020056074A1 (en) | 2020-03-19 |
| US12084426B2 (en) | 2024-09-10 |
| KR20210060516A (ko) | 2021-05-26 |
| EP3849969A1 (en) | 2021-07-21 |
| KR102793119B1 (ko) | 2025-04-07 |
| IL281371A (en) | 2021-04-29 |
| EP3849969B1 (en) | 2023-04-19 |
| ES2945220T3 (es) | 2023-06-29 |
| BR112021004310A2 (pt) | 2021-05-25 |
| JP7434294B2 (ja) | 2024-02-20 |
| US20210309633A1 (en) | 2021-10-07 |
| SG11202102406XA (en) | 2021-04-29 |
| CN112673001B (zh) | 2024-06-25 |
| CN112673001A (zh) | 2021-04-16 |
| JP2022501334A (ja) | 2022-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202190759A1 (ru) | Индазолкарбоксамиды в качестве ингибиторов киназ | |
| EA202190718A1 (ru) | Индазолкарбоксамиды в качестве ингибиторов киназ | |
| EA201991915A1 (ru) | Аминотриазолопиридины в качестве ингибиторов киназ | |
| EA202091506A1 (ru) | Триазол n-связанные карбамоил циклогексильные кислоты в качестве антагонистов lpa | |
| MX2021010198A (es) | Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales. | |
| WO2019089442A8 (en) | Aminoimidazopyridazines as kinase inhibitors | |
| EA201691302A1 (ru) | Новые гетероциклические соединения | |
| EA201892710A1 (ru) | Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa | |
| EA201991503A1 (ru) | Производные пиразола в качестве ингибиторов malt1 | |
| EA202091777A1 (ru) | Аминопирролотриазины в качестве ингибиторов киназы | |
| MX2020001352A (es) | Compuestos, composiciones y metodos. | |
| MX2020007797A (es) | Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos. | |
| MX2018016046A (es) | Quinazolina y compuestos indol para tratar trastornos medicos. | |
| EA202191519A1 (ru) | Модуляторы trex1 | |
| EA202091063A1 (ru) | Мостиковые бициклические соединения в качестве модуляторов фарнезоидного х-рецептора | |
| EA201992126A1 (ru) | Ингибиторы jak, содержащие 4-членный гетероциклический амид | |
| JOP20190174B1 (ar) | مثبطات jak1 انتقائية | |
| EA201991884A3 (ru) | Ингибиторы g12c kras | |
| MX2022003769A (es) | Indazol carboxamidas como inhibidores de cinasas. | |
| EA201592126A1 (ru) | 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b | |
| MX2019014041A (es) | Inhibidores pirazolicos de magl. | |
| EA202092962A1 (ru) | Производные пиразола в качестве ингибиторов malt1 | |
| MX2021001565A (es) | Inhibidores tipo indol y azaindol de enzimas peptidil arginina deiminasas (pad). | |
| EA201792478A1 (ru) | Соединения-ингибиторы передачи сигналов пути notch | |
| CL2021000292A1 (es) | Benzimidazoles sustituidos como inhibidores de pad4. |